{"id":396986,"date":"2020-12-10T02:16:04","date_gmt":"2020-12-10T07:16:04","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=396986"},"modified":"2020-12-10T02:16:04","modified_gmt":"2020-12-10T07:16:04","slug":"calliditas-wins-the-2020-swedenbio-award","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/","title":{"rendered":"Calliditas wins the 2020 SwedenBio Award"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">STOCKHOLM<\/span>, <span class=\"xn-chron\">Dec. 10, 2020<\/span> \/PRNewswire\/ &#8212; <b>The winner of this year&#8217;s SwedenBIO Award was announced on <span class=\"xn-chron\">Wednesday December 9<\/span><sup>th<\/sup>. Calliditas Therapeutics AB (publ) (&#8220;Calliditas&#8221;) received the award in recognition of its successful clinical development program of Nefecon, which culminated in the recent positive topline data readout of the pivotal Phase 3 NefIgArd trial.<\/b><\/p>\n<p>SwedenBio annually awards this prize to a company which has excelled in terms of R&amp;D, business development and growth whilst contributing to societal benefit. <\/p>\n<p>&#8220;This year&#8217;s winner has shown impressive professionalism and staying power with regards to the development of a completely new treatment for patients with IgA Nephropathy, a disease which lacks approved treatments today. With positive Phase 3 results in place, preparations for a submission for regulatory approval and subsequent commercialization in the US are now underway,&#8221; said Lars Adlersson, Chairman of SwedenBIO.<\/p>\n<p>The SwedenBIO Award aims to increase visibility for the life science industry by drawing attention to and rewarding successful and exemplary member companies that have particularly excelled and contributed to positive attention for the industry. A record number of companies were nominated for this year&#8217;s award. <\/p>\n<p>&#8220;We are delighted to have been selected for this prestigious award, which recognizes the Company&#8217;s longstanding commitment to addressing a significant unmet medical need for patients with IgA Nephropathy. We look forward to continuing to build on this success to deliver solutions to patients with orphan diseases&#8221;, said CEO Ren\u00e9e Aguiar-Lucander.<\/p>\n<p>\n        <b>For further information, please contact<\/b>: <\/p>\n<p>\n        <span class=\"xn-person\">Marie Galay<\/span>, IR Manager, Calliditas<\/p>\n<p>Tel.: +44 79 55 98 12 45, email: <a target=\"_blank\" href=\"mailto:marie.galay@calliditas.com\" rel=\"nofollow noopener noreferrer\">marie.galay@calliditas.com<\/a><\/p>\n<p>\n        <i>The information was sent for publication, through the agency of the contact persons set out above, on <span class=\"xn-chron\">December 10, 2020<\/span> at <span class=\"xn-chron\">08:00 a.m. CET<\/span>.<\/i>\n      <\/p>\n<p>\n        <b>About Calliditas<\/b>\n      <\/p>\n<p>Calliditas Therapeutics is a specialty pharmaceutical company based in <span class=\"xn-location\">Stockholm, Sweden<\/span> focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas&#8217; lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in <span class=\"xn-location\">the United States<\/span>. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit <a href=\"http:\/\/www.calliditas.com\" rel=\"nofollow\">www.calliditas.com<\/a> for further information.<\/p>\n<p>\u00a0<\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008885-1&amp;h=2655750658&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008885-1&amp;h=2772581205&amp;u=https%3A%2F%2Fnews.cision.com%2Fcalliditas-therapeutics%2Fr%2Fcalliditas-wins-the-2020-swedenbio-award%2Cc3252092&amp;a=https%3A%2F%2Fnews.cision.com%2Fcalliditas-therapeutics%2Fr%2Fcalliditas-wins-the-2020-swedenbio-award%2Cc3252092\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/calliditas-therapeutics\/r\/calliditas-wins-the-2020-swedenbio-award,c3252092<\/a>\n      <\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008885-1&amp;h=4106514592&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F16574%2F3252092%2F1346493.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F16574%2F3252092%2F1346493.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/16574\/3252092\/1346493.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Release<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO19816&amp;sd=2020-12-10\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/calliditas-wins-the-2020-swedenbio-award-301190083.html\">http:\/\/www.prnewswire.com\/news-releases\/calliditas-wins-the-2020-swedenbio-award-301190083.html<\/a><\/p>\n<p>SOURCE  Calliditas Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO19816&amp;Transmission_Id=202012100212PR_NEWS_USPR_____IO19816&amp;DateId=20201210\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire STOCKHOLM, Dec. 10, 2020 \/PRNewswire\/ &#8212; The winner of this year&#8217;s SwedenBIO Award was announced on Wednesday December 9th. Calliditas Therapeutics AB (publ) (&#8220;Calliditas&#8221;) received the award in recognition of its successful clinical development program of Nefecon, which culminated in the recent positive topline data readout of the pivotal Phase 3 NefIgArd trial. SwedenBio annually awards this prize to a company which has excelled in terms of R&amp;D, business development and growth whilst contributing to societal benefit. &#8220;This year&#8217;s winner has shown impressive professionalism and staying power with regards to the development of a completely new treatment for patients with IgA Nephropathy, a disease which lacks approved treatments today. With positive Phase 3 results in place, preparations for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Calliditas wins the 2020 SwedenBio Award&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-396986","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Calliditas wins the 2020 SwedenBio Award - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Calliditas wins the 2020 SwedenBio Award - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire STOCKHOLM, Dec. 10, 2020 \/PRNewswire\/ &#8212; The winner of this year&#8217;s SwedenBIO Award was announced on Wednesday December 9th. Calliditas Therapeutics AB (publ) (&#8220;Calliditas&#8221;) received the award in recognition of its successful clinical development program of Nefecon, which culminated in the recent positive topline data readout of the pivotal Phase 3 NefIgArd trial. SwedenBio annually awards this prize to a company which has excelled in terms of R&amp;D, business development and growth whilst contributing to societal benefit. &#8220;This year&#8217;s winner has shown impressive professionalism and staying power with regards to the development of a completely new treatment for patients with IgA Nephropathy, a disease which lacks approved treatments today. With positive Phase 3 results in place, preparations for &hellip; Continue reading &quot;Calliditas wins the 2020 SwedenBio Award&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-10T07:16:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO19816&amp;sd=2020-12-10\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Calliditas wins the 2020 SwedenBio Award\",\"datePublished\":\"2020-12-10T07:16:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/\"},\"wordCount\":455,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO19816&amp;sd=2020-12-10\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/\",\"name\":\"Calliditas wins the 2020 SwedenBio Award - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO19816&amp;sd=2020-12-10\",\"datePublished\":\"2020-12-10T07:16:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO19816&amp;sd=2020-12-10\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO19816&amp;sd=2020-12-10\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calliditas-wins-the-2020-swedenbio-award\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Calliditas wins the 2020 SwedenBio Award\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Calliditas wins the 2020 SwedenBio Award - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/","og_locale":"en_US","og_type":"article","og_title":"Calliditas wins the 2020 SwedenBio Award - Market Newsdesk","og_description":"PR Newswire STOCKHOLM, Dec. 10, 2020 \/PRNewswire\/ &#8212; The winner of this year&#8217;s SwedenBIO Award was announced on Wednesday December 9th. Calliditas Therapeutics AB (publ) (&#8220;Calliditas&#8221;) received the award in recognition of its successful clinical development program of Nefecon, which culminated in the recent positive topline data readout of the pivotal Phase 3 NefIgArd trial. SwedenBio annually awards this prize to a company which has excelled in terms of R&amp;D, business development and growth whilst contributing to societal benefit. &#8220;This year&#8217;s winner has shown impressive professionalism and staying power with regards to the development of a completely new treatment for patients with IgA Nephropathy, a disease which lacks approved treatments today. With positive Phase 3 results in place, preparations for &hellip; Continue reading \"Calliditas wins the 2020 SwedenBio Award\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-10T07:16:04+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO19816&amp;sd=2020-12-10","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Calliditas wins the 2020 SwedenBio Award","datePublished":"2020-12-10T07:16:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/"},"wordCount":455,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO19816&amp;sd=2020-12-10","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/","name":"Calliditas wins the 2020 SwedenBio Award - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO19816&amp;sd=2020-12-10","datePublished":"2020-12-10T07:16:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO19816&amp;sd=2020-12-10","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO19816&amp;sd=2020-12-10"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calliditas-wins-the-2020-swedenbio-award\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Calliditas wins the 2020 SwedenBio Award"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=396986"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396986\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=396986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=396986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=396986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}